[
Ewing sarcoma
Fluorine-18-fluorodeoxyglucose
Induction chemotherapy
PET/CT scan
Patient outcome assessment
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
07
01
2021
accepted:
25
02
2021
revised:
10
02
2021
pubmed:
15
3
2021
medline:
25
8
2021
entrez:
14
3
2021
Statut:
ppublish
Résumé
The application of [ Twenty-eight patients with non-metastatic EWS of bone (n = 20) and soft tissues (n = 8) who underwent a [ ΔTLG (cut-off: -60%) is the best predictor for histologic response with 100% sensitivity and 77.8% specificity. MTV [ • The variation of the PET parameter tumour lesion glycolysis (TLG) can predict the histologic response to induction chemotherapy (sensitivity 100%, specificity 77.8%), in patients with Ewing sarcoma. • The percentage variation of TLG and the value of the SUVmax at PET scan after chemotherapy show a prognostic role for future disease relapse. The combination of both the parameters identifies three prognostic classes of patients with low, intermediate and high risk of disease relapse.
Identifiants
pubmed: 33715090
doi: 10.1007/s00330-021-07841-w
pii: 10.1007/s00330-021-07841-w
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7012-7021Informations de copyright
© 2021. European Society of Radiology.
Références
Gaspar N, Hawkins DS, Dirksen U et al (2015) Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 33:3036–3046. https://doi.org/10.1200/JCO.2014.59.5256
doi: 10.1200/JCO.2014.59.5256
pubmed: 26304893
Ozaki T, Hillmann A, Hoffmann C et al (1996) Significance of surgical margin on the prognosis of patients with Ewing’s sarcoma. A report from the Cooperative Ewing’s Sarcoma Study. Cancer 78:892–900. https://doi.org/10.1002/(SICI)1097-0142(19960815)78:4<892::AID-CNCR29>3.0.CO;2-P
doi: 10.1002/(SICI)1097-0142(19960815)78:4<892::AID-CNCR29>3.0.CO;2-P
pubmed: 8756387
Grünewald TGP, Cidre-Aranaz F, Surdez D et al (2018) Ewing sarcoma. Nat Rev Dis Primers 4:5. https://doi.org/10.1038/s41572-018-0003-x
doi: 10.1038/s41572-018-0003-x
pubmed: 29977059
Bacci G, Ferrari S, Longhi A et al (2003) Therapy and survival after recurrence of Ewing’s tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol 14:1654–1659. https://doi.org/10.1093/annonc/mdg457
doi: 10.1093/annonc/mdg457
pubmed: 14581274
Stahl M, Ranft A, Paulussen M et al (2011) Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer 57:549–553. https://doi.org/10.1002/pbc.23040
doi: 10.1002/pbc.23040
pubmed: 21442722
Rodriguez-Galindo C, Billups CA, Kun LE et al (2002) Survival after recurrence of Ewing tumors: the St Jude Children’s Research Hospital experience, 1979-1999. Cancer 94:561–569. https://doi.org/10.1002/cncr.10192
doi: 10.1002/cncr.10192
pubmed: 11900241
Bosma SE, Lancia C, Rueten-Budde AJ et al (2019) Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery. Sci Rep 9:11000. https://doi.org/10.1038/s41598-019-46721-8
doi: 10.1038/s41598-019-46721-8
pubmed: 31358784
pmcid: 6662666
Wunder JS, Paulian G, Huvos AG et al (1998) The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 80:1020–1033. https://doi.org/10.2106/00004623-199807000-00011
doi: 10.2106/00004623-199807000-00011
pubmed: 9698007
Picci P, Böhling T, Bacci G et al (1997) Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing’s sarcoma of the extremities. J Clin Oncol 15:1553–1559. https://doi.org/10.1200/JCO.1997.15.4.1553
doi: 10.1200/JCO.1997.15.4.1553
pubmed: 9193352
Lin PP, Jaffe N, Herzog CE et al (2007) Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer 109:603–611. https://doi.org/10.1002/cncr.22412
doi: 10.1002/cncr.22412
pubmed: 17177205
Whelan J, Le Deley M-C, Dirksen U, et al (2018) High-dose chemotherapy and blood autologous stem-cell rescue compared with standard chemotherapy in localized high-risk Ewing sarcoma: results of Euro-E.W.I.N.G.99 and Ewing-2008. J Clin Oncol JCO2018782516. https://doi.org/10.1200/JCO.2018.78.2516
Ning MS, Perkins SM, Borinstein SC et al (2016) Role of radiation in the treatment of non-metastatic osseous Ewing sarcoma. J Med Imaging Radiat Oncol 60:119–128. https://doi.org/10.1111/1754-9485.12389
doi: 10.1111/1754-9485.12389
pubmed: 26439449
Haveman LM, Ranft A, Vd Berg H et al (2019) The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma. Cancer Med 8:1086–1094. https://doi.org/10.1002/cam4.2002
doi: 10.1002/cam4.2002
pubmed: 30790456
pmcid: 6434194
Denecke T, Hundsdörfer P, Misch D et al (2010) Assessment of histological response of paediatric bone sarcomas using FDG PET in comparison to morphological volume measurement and standardized MRI parameters. Eur J Nucl Med Mol Imaging 37:1842–1853. https://doi.org/10.1007/s00259-010-1484-3
doi: 10.1007/s00259-010-1484-3
pubmed: 20505933
Kubo T, Furuta T, Johan MP et al (2016) Percent slope analysis of dynamic magnetic resonance imaging for assessment of chemotherapy response of osteosarcoma or Ewing sarcoma: systematic review and meta-analysis. Skeletal Radiol 45:1235–1242. https://doi.org/10.1007/s00256-016-2410-y
doi: 10.1007/s00256-016-2410-y
pubmed: 27229874
Hawkins DS, Schuetze SM, Butrynski JE et al (2005) [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 23:8828–8834. https://doi.org/10.1200/JCO.2005.01.7079
doi: 10.1200/JCO.2005.01.7079
pubmed: 16314643
Raciborska A, Bilska K, Drabko K et al (2016) Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma. Clin Transl Oncol 18:189–195. https://doi.org/10.1007/s12094-015-1351-6
doi: 10.1007/s12094-015-1351-6
pubmed: 26250765
Benz MR, Czernin J, Tap WD et al (2010) FDG-PET/CT imaging predicts histopathologic treatment responses after neoadjuvant therapy in adult primary bone sarcomas. Sarcoma 2010:143540. https://doi.org/10.1155/2010/143540
doi: 10.1155/2010/143540
pubmed: 20414348
pmcid: 2855986
Kim DH, Kim SY, Lee HJ et al (2011) Assessment of chemotherapy response using FDG-PET in pediatric bone tumors: a single institution experience. Cancer Res Treat 43:170–175. https://doi.org/10.4143/crt.2011.43.3.170
doi: 10.4143/crt.2011.43.3.170
pubmed: 22022294
pmcid: 3192878
Palmerini E, Colangeli M, Nanni C et al (2017) The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas. Eur J Nucl Med Mol Imaging 44:215–223. https://doi.org/10.1007/s00259-016-3509-z
doi: 10.1007/s00259-016-3509-z
pubmed: 27645694
Casali PG, Bielack S, Abecassis N et al (2018) Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 29:iv79–iv95. https://doi.org/10.1093/annonc/mdy310
doi: 10.1093/annonc/mdy310
pubmed: 30285218
Huang T, Li F, Yan Z et al (2018) Effectiveness of 18F-FDG PET/CT in the diagnosis, staging and recurrence monitoring of Ewing sarcoma family of tumors: a meta-analysis of 23 studies. Medicine (Baltimore) 97:e13457. https://doi.org/10.1097/MD.0000000000013457
doi: 10.1097/MD.0000000000013457
Hongtao L, Hui Z, Bingshun W et al (2012) 18F-FDG positron emission tomography for the assessment of histological response to neoadjuvant chemotherapy in osteosarcomas: a meta-analysis. Surg Oncol 21:e165–e170. https://doi.org/10.1016/j.suronc.2012.07.002
doi: 10.1016/j.suronc.2012.07.002
pubmed: 22884956
Gaston LL, Di Bella C, Slavin J et al (2011) 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different. Skeletal Radiol 40:1007–1015. https://doi.org/10.1007/s00256-011-1096-4
doi: 10.1007/s00256-011-1096-4
pubmed: 21298431
Bailly C, Leforestier R, Campion L et al (2017) Prognostic value of FDG-PET indices for the assessment of histological response to neoadjuvant chemotherapy and outcome in pediatric patients with Ewing sarcoma and osteosarcoma. PLoS One 12:e0183841. https://doi.org/10.1371/journal.pone.0183841
doi: 10.1371/journal.pone.0183841
pubmed: 28841702
pmcid: 5571925
El-Hennawy G, Moustafa H, Omar W et al (2020) Different 18 F-FDG PET parameters for the prediction of histological response to neoadjuvant chemotherapy in pediatric Ewing sarcoma family of tumors. Pediatr Blood Cancer:e28605. https://doi.org/10.1002/pbc.28605
Hwang JP, Lim I, Kong C-B et al (2016) Prognostic value of SUVmax measured by pretreatment fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with Ewing sarcoma. PLoS One 11:e0153281. https://doi.org/10.1371/journal.pone.0153281
doi: 10.1371/journal.pone.0153281
pubmed: 27100297
pmcid: 4839768
Salem U, Amini B, Chuang HH et al (2017) 18F-FDG PET/CT as an Indicator of Survival in Ewing Sarcoma of Bone. J Cancer 8:2892–2898. https://doi.org/10.7150/jca.20077
doi: 10.7150/jca.20077
pubmed: 28928879
pmcid: 5604439
Shi J, Yang J, Ma X, Wang X (2020) Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study. J Orthop Surg Res 15:88. https://doi.org/10.1186/s13018-020-01607-8
doi: 10.1186/s13018-020-01607-8
pubmed: 32131863
pmcid: 7055127
WHO Classification of Tumours Editorial Board (2020) Soft tissue and bone tumours. WHO classification of tumours series, Vol. 3, 5th edn. International Agency for Research on Cancer, Lyon, France. https://publications.Iarc.fr/588
Salah S, Abuhijla F, Ismail T et al (2020) Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol. Clin Transl Oncol 22:878–883. https://doi.org/10.1007/s12094-019-02202-y
doi: 10.1007/s12094-019-02202-y
pubmed: 31429039